 Fenoldopam
"Fenoldopam" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
| Descriptor ID |
D018818
|
| MeSH Number(s) |
D03.438.079.300
|
| Concept/Terms |
SKF-82526J- SKF-82526J
- SKF 82526J
- SKF82526J
- SK&F-82526J
- SK&F 82526J
- SK&F82526J
SK&F-82526- SK&F-82526
- SK&F 82526
- SK&F82526
- SKF-82526
- SKF 82526
- SKF82526
|
Below are MeSH descriptors whose meaning is more general than "Fenoldopam".
Below are MeSH descriptors whose meaning is more specific than "Fenoldopam".
This graph shows the total number of publications written about "Fenoldopam" by people in this website by year, and whether "Fenoldopam" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1988 | 0 | 2 | 2 | | 1989 | 0 | 1 | 1 | | 1990 | 0 | 2 | 2 | | 1991 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fenoldopam" by people in Profiles.
-
Elliott WJ. Clinical features and management of selected hypertensive emergencies. J Clin Hypertens (Greenwich). 2004 Oct; 6(10):587-92.
-
Ikegami H, Kajikawa S, Ito K, Nii A, Okamiya H, Nakayama H, Doi K. Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators. Exp Toxicol Pathol. 2002 Jul; 54(1):1-7.
-
Ikegami H, Shishido T, Ishida K, Hanada T, Nakayama H, Doi K. Histopathological and immunohistochemical studies on arteritis induced by fenoldopam, a vasodilator, in rats. Exp Toxicol Pathol. 2001 Apr; 53(1):25-30.
-
Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 1993 Aug; 95(2):161-8.
-
Gretler DD, Elliott WJ, Moscucci M, Childers RW, Murphy MB. Electrocardiographic changes during acute treatment of hypertensive emergencies with sodium nitroprusside or fenoldopam. Arch Intern Med. 1992 Dec; 152(12):2445-8.
-
Elliott WJ, Karnezis TA, Silverman RA, Geanon J, Tripathi RC, Murphy MB. Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans. Clin Pharmacol Ther. 1991 Mar; 49(3):285-93.
-
Elliott WJ, Weber RR, Nelson KS, Oliner CM, Fumo MT, Gretler DD, McCray GR, Murphy MB. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 1990 Mar; 81(3):970-7.
-
Murphy MB, Elliott WJ. Dopamine and dopamine receptor agonists in cardiovascular therapy. Crit Care Med. 1990 Jan; 18(1 Pt 2):S14-8.
-
Karnezis TA, Tripathi BJ, Dawson G, Murphy MB, Tripathi RC. Effects of dopamine receptor activation on the level of cyclic AMP in the trabecular meshwork. Invest Ophthalmol Vis Sci. 1989 Jun; 30(6):1090-4.
-
Karnezis TA, Murphy MB, Weber RR, Nelson KS, Tripathi BJ, Tripathi RC. Effects of selective dopamine-1 receptor activation on intraocular pressure in man. Exp Eye Res. 1988 Nov; 47(5):689-97.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|